Seminars in Oncology
Volume 33 , Pages 1-2 , December 2006

Introduction

  • David S. Alberts (Guest Editor)

      Affiliations

    • Corresponding Author InformationAddress reprint requests to David S. Alberts, MD, Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ 85274, USA

References 

  1. National Cancer Institute: NCI Clinical Announcement on Intraperitoneal Therapy for Ovarian Cancer. Available at: http://www.cancer.gov/clinicaltrials/developments/IPchemo-digest (accessed Dec 6, 2006)
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin. 2006;56:106–130
  3. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage II ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200
  4. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 2002;20:1248–1259
  5. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III & IV ovarian cancer. N Engl J Med. 1996;334:1–6
  6. Theodoridis TD, Bontis JN. Laparoscopy and oncology: Where do we stand today?. Ann N Y Acad Sci. 2003;997:282–291
  7. Dedrick R, Myers C, Bungay P, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–11
  8. Litterst CL, Torres IJ, Arnold S, et al. Absorption of antineoplastic drugs following large-volume ip administration of rats. Cancer Treat Rep. 1982;66:147–155
  9. Los G, Verdegaal EM, Mutsaers PH, et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159–165
  10. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group Study. J Clin Oncol. 1998;16:2620–2624
  11. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9:1801–1805
  12. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955
  13. Armstrong DK, Bundy B, Wenzel L, et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in stage III ovarian cancer: A Gynecologic Oncology Group Study. N Engl J Med. 2006;354:34–43
  14. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–1007
  15. National Cancer Institute. NCI Clinical Announcement. Intraperitoneal Chemotherapy for Ovarian Cancer. Available at: http://ctep.cancer.gov/highlights/clin_annc_010506.pdf (accessed July 7, 2006)
  16. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer (A Gynecologic Oncology Group study). Gynecol Oncol. 2006;100:27–32

 This activity is supported by an unrestricted educational grant from MedImmune Oncology, Inc, a subsidiary of MedImmune, Inc.

 Dr Alberts has received grant and research support from and serves on the speakers bureau for MedImmune, Inc. He is also a paid consultant for Amgen Inc.

PII: S0093-7754(06)00427-1

doi: 10.1053/j.seminoncol.2006.11.005

Seminars in Oncology
Volume 33 , Pages 1-2 , December 2006

Article Tools